Dr. Ma is an Associate Professor in the Department of Pharmaceutical Sciences and a member of the Center for Pharmacogenetics, University of Pittsburgh School of Pharmacy. He obtained his Ph.D. in Pharmacology and Toxicology from Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2003. From there, he went to National Institutes of Health (NIH) and completed his postdoctoral training in Dr. Frank J. Gonzalez’s laboratory in 2008. Afterward, he worked as an Assistant Professor at University of Kansas Medical Center, until he joined the University of Pittsburgh in 2013.

Dr. Ma’s research interests include drug-induced liver injury, toxicometabolomics, and safety-based personalized medicine.

• Ma X, Shah Y, Cheung C, Guo GL, Feigenbaum L, Krausz KW, Idle JR, Gonzalez FJ. The pregnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos. 2007 Feb;35(2):194-200. PubMed PMID: 17093002.
• Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR, Gonzalez FJ. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther. 2007 Jul;322(1):391-8. PubMed PMID: 17442842.
• Ma X, Cheung C, Krausz KW, Shah YM, Wang T, Idle JR, Gonzalez FJ. A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab Dispos. 2008 Dec;36(12):2506-12. PubMed PMID: 18799805; PubMed Central PMCID: PMC2678901.
• Guettier JM, Gautam D, Scarselli M, Ruiz de Azua I, Li JH, Rosemond E, Ma X, Gonzalez FJ, Armbruster BN, Lu H, Roth BL, Wess J. A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19197-202. PubMed PMID: 19858481; PubMed Central PMCID: PMC2767362.
• Li F, Lu J, Ma X. Profiling the reactive metabolites of xenobiotics using metabolomic technologies. Chem Res Toxicol. 2011 May 16;24(5):744-51. PubMed PMID: 21469730; PubMed Central PMCID: PMC3100669.
• Li F, Lu J, Cheng J, Wang L, Matsubara T, Csanaky I, Klaassen CD, Gonzalez FJ, Ma X. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med. 2013; 19(4):418-20. PMID: 23475203.
• Li F, Lu J, Ma X. CPY3A4-mediated α-hydroxyaldehyde formation in saquinavir metabolism. Drug Metab Dispos. 2014; 42(2):213-20. PubMed PMID: 24212380; PubMed Central PMCID: PMC3912542.
• Gonzalez FJ, Fang ZZ, Ma X. Transgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity. Expert Opin Drug Metab Toxicol. 2015; 11(6):869-81. PubMed PMID: 25836352.
• Sachar M, Anderson KE, Ma X. Protoporphyrin IX: the Good, the Bad, and the Ugly. J Pharmacol Exp Ther. 2016 Feb;356(2):267-75. PubMed PMID: 26588930.
• Sachar M, Ma X. Role of ABCG2 in liver injury associated with erythropoietic protoporphyria. Hepatology. 2015 Sep 24. doi: 10.1002/hep.28249. [Epub ahead of print] PubMed PMID: 26403458.
• Sachar M, Li F, Liu K, Wang P, Lu J, Ma X. Chronic Treatment with Isoniazid Causes Protoporphyrin IX Accumulation in Mouse Liver. Chem Res Toxicol. 2016 Aug 15;29(8):1293-7. doi: 10.1021/acs.chemrestox.6b00121. Epub 2016 Aug 2. PubMed PMID: 27438535; PubMed Central PMCID: PMC5316289.
• Wang P, Shehu AI, Ma X. The Opportunities of Metabolomics in Drug Safety Evaluation. Curr Pharmacol Rep. 2017 Feb;3(1):10-15. doi: 10.1007/s40495-016-0079-5. Epub 2017 Jan 3. PubMed PMID: 28758057; PubMed Central PMCID: PMC5526643.
• Wang P, Sachar M, Guo GL, Shehu AI, Lu J, Zhong XB, Ma X. Liver Metabolomics in a Mouse Model of Erythropoietic Protoporphyria. Biochem Pharmacol. 2018 Aug;154:474-481. PubMed PMID: 29906468.
• Zhu J, Wang P, Shehu AI, Lu J, Bi H, Ma X. Identification of novel pathways in idelalisib metabolism and bioactivation. Chem Res Toxicol. 2018 Jul 16;31(7):548-555. PubMed PMID: 29896955.
• Jiang Y, Feng D, Ma X, Fan S, Gao Y, Fu K, Wang Y, Sun J, Yao X, Liu C, Zhang H, Xu L, Liu A, Gonzalez FJ, Yang Y, Gao B, Huang M, Bi H. Pregnane X Receptor Regulates Liver Size and Liver Cell Fate via Yes-associated Protein Activation. Hepatology. 2018 Jul 26. doi: 10.1002/hep.30131. [Epub ahead of print] PubMed PMID: 30048004.
• Saggi H, Maitra D, Jiang A, Zhang R, Wang P, Cornuet P, Singh S, Locker J, Ma X, Dailey H, Abrams M, Omary MB, Monga SP, Nejak-Bowen K. Loss of hepatocyte β-Catenin protects mice from experimental porphyria-associated liver injury. J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32442-5. PubMed PMID: 30287339.
• Zhu J, Wang P, Li F, Lu J, Shehu AI, Xie W, McMahon D, Ma X. CYP1A1 and 1B1-mediated metabolic pathways of dolutegravir, an HIV integrase inhibitor. Biochem Pharmacol. 2018 Oct 17;158:174-184. PubMed PMID: 30342022.

• 2007 Fellows Award for Research Excellence, sponsored by NIH
• 2007 Postdoctoral Scientist Award in Toxicology (1st place), sponsored by the American Society for Pharmacology and Experimental Therapeutics (ASPET)
• 2008 Fellows Award for Research Excellence, sponsored by NIH
• 2018 The ASPET 2018 Junior Investigator Award, sponsored by the Toxicology Division, ASPET.

• "Metabolomic Analysis Reveals Novel Mechanisms of Drug Toxicity". Drug Metabolism, Gordon Research Conferences. Holderness, New Hampshire. 2012.
• “The Role of Xenobiotic Nuclear Receptors in Drug Metabolism and Metabolism-Mediated Liver Injury”. 2nd Mitigation Strategies for Reactive Metabolites. Boston, Massachusetts. 2012.
• “Humanized mouse models and drug toxicity” 10th International Society for the Study of Xenobiotics (ISSX) Meeting. Toronto, Canada, 2013.
• “Human PXR models provide novel insights into adverse drug reactions associated with anti-TB and anti-HIV drugs”. Therapeutics Research Program, Division of AIDS, NIAID, NIH, 2013.
• “The opportunities and challenges of metabolomics in drug safety evaluation”. 19th North American ISSX Meeting / 29th JSSX Meeting. San Francisco, California, 2014.
• “Genetically Engineered Mouse Models in Preclinical Studies of Drug Metabolism & Toxicity”. The Delaware Valley Drug Metabolism Discussion Group. West Chester, Pennsylvania, 2015.
• “PXR-humanized Mouse Models for Drug Testing”. The Liver Meeting, Special Interest Group (SIG) on Hepatotoxicity. San Francisco, CA, 2015.
• “Metabolomic applications to guide the mechanistic understanding of drug-induced liver injury (DILI)”. The 21st International Symposium on Microsomes and Drug Oxidations. Davis, CA, 2016.
• “The Gut-liver Axis in Eythropoietic Protoprophyria”. ASPET Annual Meeting at Experimental Biology. Chicago, IL, 2017

• R01AI131983, NIAID/NIH, 2017-2022. Pharmacoenhancers for antiretroviral therapy: safety and future development. PI: Xiaochao Ma.
• R01GM118367, NIGMS/NIH, 2016-2020. Short- or long-term impacts of drug exposure at early life on drug metabolism, therapeutic efficacy, and drug-induced toxicity. PI: Xiaobo Zhong. Role of Xiaochao Ma: Co-I.

View CV

In some browsers, the CV link may not automatically open. You may right-click on the link to open in a new tab to view the CV file.